Top 5 Small-Cap Stocks With Highest Upside Potential

Page 5 of 5

1. Global Blood Therapeutics, Inc. (NASDAQ:GBT)

Number of Hedge Fund Holders: 30

Global Blood Therapeutics, Inc. (NASDAQ:GBT) operates as a biopharmaceutical company and is involved in the discovery, development, and delivery of therapeutics that battle sickle cell disease (SCD). On May 4, the company posted earnings for the fiscal first quarter of 2022 in which it exceeded EPS estimates by $0.10. The company reported a loss per share of $1.26 and generated quarterly revenues of $55.16 million, up 41.28% year over year from $39.04 million.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) is gaining prominence in the healthcare industry and winning FDA approvals for its therapeutics. This February, the company’s SCD medication Oxbryta was approved by the European Commission for the treatment of patients that are at least 12 years and above. Oxbryta is FDA approved in the U.S. for use in children at least 4 years of age.

On May 11, Wedbush analysts Andreas Argyrides and Liana Moussatos added Global Blood Therapeutics, Inc. (NASDAQ:GBT) to Wedbush’s Best Ideas List. Argyrides and Moussatos added that the company reported 1,200 additional prescriptions for Oxbryta in Q1, and see this number only increasing in the following quarters. The analysts are bullish on big pharma and see Global Blood Therapeutics, Inc. (NASDAQ:GBT) gaining more market share in the quarters to come, which makes Global Blood Therapeutics, Inc. (NASDAQ:GBT) one of the top small-cap stocks with the highest upside potential. Argyrides and Moussatos reiterated their Outperform rating and $73 price target on the stock.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) is a popular pick among elite hedge funds. Insider Monkey found 30 hedge funds that held stakes in the company at the close of Q4 2021. The total value of these stakes came in at $499.21 million, up from $382.92 million in the prior quarter with 23 positions. The hedge fund sentiment for the stock is positive.

As of March 31, 2022, Perceptive Advisors is the dominating shareholder in Global Blood Therapeutics, Inc. (NASDAQ:GBT) owning over 3.89 million shares of the company. This equates to a stake value of $134.83 million and covers 2.7% of Perceptive Advisors’ 13F portfolio.

You can also take a look at 10 Best Small-Cap Stocks To Buy Now and 15 Best Small-Cap Healthcare Stocks to Buy.

Page 5 of 5